Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
EPS at Rs 32.19
Substantial reduction in losses
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
Demand normalisation post the second wave contributed to the steady growth
Anti-malaria API facility will be operational in 15-18 months
Subscribe To Our Newsletter & Stay Updated
